Introduction
============

Cardiovascular disease is the leading cause of mortality and morbidity in industrialized nations. Since the discovery of the first key determinant of heart development---*tinman*---in *Drosophila* ([@bib3]; [@bib8]), numerous regulators, including transcription factors, cell signaling molecules, extracellular matrix proteins, and microRNAs have provided an understanding of an increasingly complex network that guides cardiac specification, differentiation, function, and maturation in all organisms that possess a heart ([@bib7]; [@bib44]; [@bib57]; [@bib52]).

The fruit fly *Drosophila* is an attractive model system to study various human diseases, including cardiac disease ([@bib58]; [@bib6]). The *Drosophila* heart is a simple linear tube comprised of myocardial and pericardial cells, which is reminiscent of the primitive vertebrate embryonic heart. Despite the simplicity of the structure, the genetic and molecular mechanisms that orchestrate heart formation are remarkably conserved between flies and vertebrates ([@bib9]; [@bib19]). Moreover, recent studies using multiple functional assays revealed extensive conservation of gene functions required for maintaining normal heart physiology in the adult ([@bib7]; [@bib42]; [@bib52],[@bib53]). Combined with the powerful genetic tools available in the fly, screens to identify molecular--genetic pathways involved in cardiac contractility and rhythm can now be executed, leading to the identification of novel cardiac regulators that can then be examined in mammals ([@bib1]; [@bib58]; [@bib64]; [@bib41]).

Tinman and its mammalian homologue Nkx2-5 are homeobox transcription factors that play crucial roles in heart development and function ([@bib48]). Whereas ablation of *tinman* in the *Drosophila* embryo abolishes heart formation, targeted deletion of *tinman* at later stages reveals additional requirements for *tinman* in maintaining normal adult heart function and physiology ([@bib66]). This is reminiscent of Nkx2-5 in vertebrates, which is required for establishing heart function in the developing mouse embryo, for example, and also later for its maintenance in the adult ([@bib46]). The genetic networks that Nkx2-5 participates in and how these interactions regulate adult heart functions are not well understood. A major reason for this is that it is often difficult to identify and study polygenic modifiers of (cardiac) disease in a vertebrate system, in part because the organism viability is critically dependent on a functional heart.

In a previous study, we identified a genetic interaction between *neuromancer* (*nmr)*/*Tbx20* and *tinman/Nkx2-5* in the adult *Drosophila* heart ([@bib53]). Here, we performed a deletion screen in a reduced *tinman* genetic background to identify genes that interact with *tinman* to maintain normal heart function in *Drosophila*. One of the strong genetic interactions causing cardiac dysfunction was between *tinman* and the gene *Cdc42*, a Rho family member of the small GTPase family, suggesting a role for *Cdc42* in maintaining heart function. Indeed, dominant-negative interference with *Cdc42* function alone in the adult fly heart compromises cardiac performance. We also identified potential downstream effectors of the *Cdcd42*--*tinman* interaction, including *dSUR* and *slowpoke*, which code for two K^+^ channels that are known to be required for heart function.

*Cdc42* has a conserved, essential role in regulating cell cycle, directed migration, epithelial polarity, and cell fate specification ([@bib14]; [@bib27]); and in adult mouse cardiomyocytes Cdc42 is involved in growth and prevention of hypertrophy ([@bib37]). Here, we find that the genetic interaction between *Cdc42* and *Nkx2-5* is conserved in the mouse, and that Cdc42 and Nkx2-5 synergize to regulate heart function and physiology, which is likely mediated by miR-1. These data suggest that *Cdc42* plays a conserved role in establishing and maintaining normal heart function downstream of, and potentially in concert with, the cardiac determinant *tinman/Nkx2-5*.

Results
=======

Genetic interactions between *Cdc42* and *tinman* in regulating heart performance in *Drosophila*
-------------------------------------------------------------------------------------------------

Increasing evidence suggests that the conserved cardiogenic transcription factor network that regulates heart formation also functions to establish and maintain cardiac performance in the adult ([@bib66]; [@bib42]; [@bib53]; [@bib49]). To uncover genes that interact with this transcription factor network in adult heart function, we conducted a screen for mutations that aggravate the cardiac stress response of flies heterozygous for *tinman*. We examined cardiac performance of double-heterozygous flies for *tinman* and deficiency lines (97 in total) covering the X chromosome and part of the second chromosome (34% of the genome, see [Table S1](http://www.jcb.org/cgi/content/full/jcb.201006114/DC1)). We identified several categories of candidate genes suggestive of a developmental interaction: for example, the trans configuration of *tinman* with the deficiency line 7783 is lethal ([Fig. 1 A](#fig1){ref-type="fig"}, group II bottom), possibly due to a vital interaction with the *dpp* gene (contained within 7783) that is critically involved in cardiac induction during early embryogenesis, along with *tinman* ([@bib52]). In another category, the heterozygous candidate lines by themselves exhibit cardiac defects (increased pacing-induced heart failure rate, see Materials and methods; e.g., lines 7708 and 7499; [Fig. 1 A](#fig1){ref-type="fig"}, group I), indicating that haploinsufficiency in one or more genes covered by these deficiencies results in cardiac deficits. Of particular interest, the "strong enhancer" category of deficiency lines shows an interaction when in trans with *tinman* (\>50%), but when crossed to wild type (*w^1118^*) exhibits a low rate of heart failure (\<20%) that is similar to wild-type flies (e.g., 7717, 7721; [Fig. 1 A](#fig1){ref-type="fig"}, group II top). We chose for further analysis line 7721, which exhibits a robust interaction with *tinman*, in that the trans combination shows a threefold increase in susceptibility to pacing-induced heart failure (7721 x *tin^346^*) compared with single heterozygotes (e.g., 7721 x *w^1118^*).

![**Genetic screen identifying *Cdc42*.** (A) Candidate deficiency lines interacting with *tin^346^* (susceptibility to pacing-induced heart arrest or fibrillation). (B) Genetic interaction between *tinman*, *Cdc42*, and deficiency 7721. *Cdc42^+/−^;tin^+/−^* flies show dramatic increase in pacing-induced heart arrest or fibrillation rate compared with *Cdc42^+/−^* or *tin^+/−^* (Chi square analysis: \*, P \< 0.01). (C) TARGET-mediated overexpression (see Materials and methods) of dominant-negative *Cdc42* (*Cdc42^N17^*) in the adult heart results in elevated heart dysfunction (\*, P \< 0.01). Each bar in B and C represents a single experiment. *n*, number of flies tested.](JCB_201006114_GS_Fig1){#fig1}

Among the nine genes deleted by the deficiency 7721 (Df(1)Exel6253, referred to as Df(*Cdc42*)) is the small GTPase encoded by *Cdc42*, which is known for its role in cell cycle regulation and actin cytoskeletal rearrangement ([@bib20]; [@bib23]; [@bib30]; [@bib28]; [@bib27]) and has been implicated in cardiomyocyte growth and hypertrophy ([@bib15]; [@bib37]). We took a candidate gene approach and examined whether known *Cdc42* loss-of-function mutants also interacted with *tinman*. Both *tin^EC40^* ([@bib8]) and *tin^346^* ([@bib3]) heterozygotes show a dramatic increase in heart failure rate in a *Cdc42^3^* heterozygous background ([@bib21]; [@bib23]), similar to that observed for *tinman, Df(1)Exel6253* double heterozygotes ([Fig. 1 B](#fig1){ref-type="fig"}). This suggests that the interaction between *tinman* and *Cdc42* is required for the maintenance of proper adult heart function.

*Cdc42*-encoded RhoGTPase is required for adult cardiac function in *Drosophila*
--------------------------------------------------------------------------------

To examine a possible role for *Cdc42* in the fly heart, we asked whether *Cdc42* plays a muscle- or cardiac-autonomous role. For this purpose, we expressed a dominant-negative form of *Cdc42* (UAS-*Cdc42^N17^*; [@bib36]) specifically in the adult heart using *tinCΔ4Gal4* (a UAS-Gal4 system that drives gene expression only in myocardial cells; [@bib50]), or in all mesoderm using *24BGal4* (drives gene expression pan-mesodermally; [@bib12]). The UAS-GAL4 system has two parts: the GAL4 gene that encodes the yeast transcriptional activator protein Gal4, and the upstream activation sequence (UAS), which is a short section of the promoter region to which Gal4 specifically binds to activate gene transcription ([@bib12]). By using the TARGET system (Gal4/Gal80, see Materials and methods; [@bib38]) in combination with *UASCdc42^N17^*, we specifically interfered with *Cdc42* function in the adult heart without disturbing its function in the embryo. Interference with *Cdc42* function specifically in the heart within the first week of adult life causes a dramatic increase in pacing-induced heart failure ([Fig. 1 C](#fig1){ref-type="fig"}), suggesting that *Cdc42* is essential for maintaining normal heart function. These *Cdc42^N17^* mutant hearts, when assessed for their beating pattern, also show increased incidence of arrhythmias and an overall lower heart rate, due to lengthening of diastolic intervals, compared with controls ([Fig. 2, A--F](#fig2){ref-type="fig"}). Using the mean standard deviation of heart period as an indicator of heart rhythm disturbance ("arrhythmia index"; [@bib42]; [@bib22]), we found a dramatic increase in arrhythmias in *Cdc42^N17^* hearts ([Fig. 2 F](#fig2){ref-type="fig"}). These effects are more dramatic than in *Cdc42* heterozygotes and together strongly support a crucial requirement for *Cdc42* in regulating adult heart function.

![**Cdc42 is required for adult heart function in flies.** (A--C) Cardiac M-mode traces prepared from high speed movies of semi-intact flies. (A) M-mode from control flies shows a regular beating pattern. (B and C) Arrhythmic heart beats are evident in flies overexpressing *Cdc42^N17^* using tinCΔ4-Gal4 (G) or 24BGal4 (H). (A′--C′) Heart period histograms. (D--F) Statistical analysis of *Cdc42^N17^* mutant heart contractions (relative quantification \[RQ\] compared with control). Disruption of *Cdc42* in the adult heart results in longer diastolic but not systolic intervals (D and E) and in increased incidence of arrhythmias (F). Error bars represent SEM. (G--I) α-Actinin labeling of the adult heart (one segment). *Cdc42^N17^* adult heart or *Cdc42, tinman* double heterozygotes show disruption of cardiomyocyte myofibrillar alignment. Bars, 50 µm. (J and K) Quantification of abnormalities in *Cdc42^N17^* and *Cdc42^+/−^;tin^+/−^* hearts. Severity is determined by the average number of segments with significant abnormal myofiber structure. *n*, number of flies tested. Unpaired Student\'s *t* test: \*, P \< 0.05.](JCB_201006114_RGB_Fig2){#fig2}

The defective *Cdc42^N17^* adult hearts also showed abnormalities in the cellular architecture of the cardiomyocytes, as manifest by severely misaligned myofibrils and irregularities in the repeated Z-line pattern ([Fig. 2, G--I](#fig2){ref-type="fig"}). These structural abnormalities in *Cdc42* mutant hearts are consistent with *Cdc42*\'s role in actin filament assembly, also observed in *Drosophila* nurse cells, neurons, and epithelial cells ([@bib23]; [@bib30]; [@bib31]). During *Drosophila* dorsal closure, Cdc42 activates the serine/threonine protein kinase Pak to regulate dynamic actin structure and epithelial plasticity ([@bib26]; [@bib4]). Therefore, we reasoned that Cdc42 may act through the Pak pathway to regulate actin filament assembly and thus myofibrillar structure in the fly heart. To test this hypothesis, we generated *Cdc42, Pak* transheterozygotes and examined their cardiac structure and function ([Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201006114/DC1)). Indeed, the majority of these transheterozygous hearts exhibited heart tube abnormalities where the myofibrils were misaligned or had gaps between the fibrils, whereas the hearts from single heterozygotes appear wild type (Fig. S1, A--C). Furthermore, functional analyses revealed that *Cdc42, Pak* double heterozygotes also exhibited other contractile abnormalities, which are likely due to the observed defects in myofibrillar organization. In contrast, the heart beat intervals and overall rhythmicity are not affected (Fig. S1, D--F), compared with *Cdc42*\'s interaction with *tinman* ([Fig. 2, A--F](#fig2){ref-type="fig"}). These data are consistent with a *Cdc42* interaction with *Pak* in regulating cardiac actin alignment and thus the myofibrillar organization of the heart, but perhaps less so in regulating the heart rate and rhythm.

*Cdc42--tinman* interaction contributes to adult heart structure and function
-----------------------------------------------------------------------------

To further explore the *Cdc42--tinman* interaction, we examined the contractility and beating patterns in double-heterozygous hearts. Compared with the single heterozygotes, both *tin^346^*/*Cdc42^3^* and *tin^346^*/*Df(Cdc42)* flies exhibit an irregular beating pattern and a tendency toward longer diastolic intervals ([Fig. 3, A--C](#fig3){ref-type="fig"}), similar to *Cdc42^N17^* hearts ([Fig. 2, A--F](#fig2){ref-type="fig"}). The elevated arrhythmias are also illustrated in the broadening of the heart period distribution in the double heterozygotes ([Fig. 3](#fig3){ref-type="fig"}, A′ and B′). Thus, combined partial loss of *Cdc42* and *tinman* function synergistically compromises heart function. In addition, *Cdc42* also shows a synergistic interaction with *tinman* in establishing a regular myofibrillar structure of the adult heart ([Fig. 2, I and K](#fig2){ref-type="fig"}). In contrast, a transheterozygous combination of *Cdc42* with Df(2L)Exel6012, a deficiency covering the *nmr/Tbx20* locus that also interacts with *tinman* ([@bib53]), fails to exhibit such an interaction (Fig. S1, G--L). Thus, *Cdc42* seems to engage in a specific genetic interaction with *tinman* to regulate adult heart function in the adult fly.

![***Cdc42* and *tinman* interact to maintain normal cardiac contraction.** (A and B) Representative M-mode traces showing arrhythmic heart contractions in *Df(Cdc42)/+;tin^346^/+* (B), compared with single heterozygotes *Df(Cdc42)/+* (A). (A′--B′) Heart period histograms. (C) Statistical analysis of heart contraction in controls (*w, tin^346^/+, Cdc42^3^/+, Df(Cdc42)/+*) and *Cdc42^3^/+;tin^346^/+* and *Df(Cdc42)/+;tin^346^/+* flies, shown as relative quantification (RQ). Error bars represent SEM; \*, P \< 0.05 (one-way ANOVA). (D and E) RQ of *dSUR* (A) and *slowpoke* (B) mRNA in 1-wk-old adult hearts (normalized to *rp49*, ribosomal protein 49) relative to control (*w*). Double heterozygotes Df(*Cdc42*)/+;*tin^346^*/+, Df(*Cdc42*)/+;*tin^EC40^*/+, and *Cdc42^3^*/+;*tin^346^*/+ showed lower expression than *tinman* or *Cdc42* heterozygotes, or *w* controls. (F) Functional analyses of *Cdc42,dSUR* and *Cdc42,slo* double heterozygotes showed a significant increase in the arrhythmia index. (G) Luciferase assay using the dSUR T3 enhancer ([@bib2]). Note the increased relative luciferase activity (RLA) by transfection of Tin was further enhanced by cotransfection with Cdc42 or Pnr, but not when Pnr and Cdc42 were cotransfected. Mutation of the Tin site abolished the responsiveness. Experiments were repeated three times. Error bars represent SEM. Unpaired Student's *t* test: \*, P \< 0.05; \*\*, P \< 0.01.](JCB_201006114R_GS_Fig3){#fig3}

To determine how *Cdc42* and *tinman* interact to maintain heart function, we examined the gene expression levels of a cadre of cardiac-specific potential targets or effectors of the *Cdc42*--*tinman* interaction by quantitative RT-PCR (qPCR; see Materials and methods for complete list). In particular, we focused on ion channel genes that have previously been shown to regulate heart function in the adult fly ([@bib10]; [@bib2]; [@bib42]; [@bib52]). Of these candidates, the two potassium channels *dSUR* and *slowpoke* were most severely down-regulated ([Fig. 3, D and E](#fig3){ref-type="fig"}; see [Fig. S2, A and B](http://www.jcb.org/cgi/content/full/jcb.201006114/DC1), for examples of genes showing no changes), and they have previously been shown to be required for normal cardiac performance ([@bib32]; [@bib2]). To determine whether *Cdc42* genetically interacted with these two potential downstream effectors, we generated *Cdc42+/−;dSUR+/−* and *Cdc42+/−;slo+/−* flies. These transheterozygotes showed a defective cardiac structure as determined by α-Actinin staining (Fig. S2, C--H). These hearts do not show dramatically altered heart beat intervals (Fig. S2, I and J), but they do beat more arrhythmically than single heterozygous controls, as indicated by an increased arrhythmia index ([Fig. 3 I](#fig3){ref-type="fig"}). This suggests that *Cdc42* indeed interacts with *dSUR* and *slo* to ensure normal heart structure and function. This interaction phenotype also suggests the possibility that malfunctioning ion channels may contribute to the structural remodeling (see Discussion). Interestingly, expression of *dSUR* is also down-regulated in the heart with age, and old fly hearts exhibit functional abnormalities, including an increased incidence of arrhythmias and pacing-induced heart failure ([@bib2]; [@bib42]), similar to what we observed in the (young) *Cdc42+/−;tin+/−* adult flies.

To further explore how *Cdc42* interacts with *tinman* in regulating *dSUR* expression, we took advantage of a previously published enhancer element of dSUR ([@bib2]) and performed luciferase assays in *Drosophila* S2 cells transfected with *Cdc42* and/or *tinman* expression constructs. Consistent with the previous results, the *dSUR* enhancer element is responsive to cotransfection with a *tinman* expression construct ([Fig. 3 G](#fig3){ref-type="fig"}). Importantly, luciferase activity is dramatically enhanced by addition of a *Cdc42* construct whereas transfection of *Cdc42* by itself did not exert any effect on this enhancer ([Fig. 3 G](#fig3){ref-type="fig"}). Mutating the Tinman binding site in this enhancer abolished the responsiveness ([Fig. 3 G](#fig3){ref-type="fig"}). Conversely, addition of Cdc42 did not enhance the transcriptional activity of another transcription factor, the GATA factor Pannier, which in turn synergizes dramatically with Tinman in this assay ([Fig. 3 G](#fig3){ref-type="fig"}), as well as in vivo ([@bib2]). These data suggest that Cdc42 may cooperate with Tinman (but not with Pannier) to activate the *dSUR* enhancer directly rather than by acting indirectly through separate pathways in the regulation of *dSUR* expression. This is consistent with the idea that the changes in expression of these ion channel genes may not be secondary to the sarcomeric defects in *Cdc42+/−;tin+/−* hearts. However, indirect mechanisms of Cdc42 interaction with Tinman's transcriptional activity cannot be ruled out, as it is also possible that the myofibril alignment defects are secondary to the contractility defects, but all these considerations have to await future analysis. Based on the genetic interaction of *Cdc42* with *tinman* presented here, it is suggested that Rho GTPases may represent a novel class of cardiac disease genes and/or act as polygenic interactors with known heart disease genes, such as *tinman/Nkx2-5*.

Cdc42 interacts with Nkx2-5 in modulating adult mouse heart function
--------------------------------------------------------------------

Because *Cdc42* and *tinman* are conserved in vertebrates, we tested whether the interaction between them is also conserved in mice. We first generated compound *Mm Cdc42^del/+^;Nkx2-5^del/+^* mice, which are viable at normal Mendelian ratios (unpublished data), and compared them to single-heterozygous littermates. We used high-resolution echocardiography to monitor structural and functional aspects of the postnatal mouse heart ([Fig. 4, A--E](#fig4){ref-type="fig"}). *Mm Cdc42^+/+^;Nkx2-5^+/+^*, *Mm Cdc42^+/+^;Nkx2-5^del/+^*, *Mm Cdc42^del/+^;Nkx2-5^+/+^*, and *Mm Cdc42^del/+^;Nkx2-5^del/+^* adult mice were subjected to serial imaging at 4--12 wk after birth. At 4 wk of age, cardiac function in single heterozygotes (*MmCdc42^del/+^* or *Nkx2-5^del/+^*) was not significantly different from wild-type littermates, whereas double heterozygotes showed declining heart function as indicated by decreased fraction of blood ejected from the left ventricle with each contraction (ejection fraction, EF), the fractional shortening of the ventricular chamber (fractional shortening, FS), volume of blood ejected with each heart beat (stroke volume, SV), and cardiac output (CO; see [Fig. 4, A--D](#fig4){ref-type="fig"} for quantification and [Fig. 4 E](#fig4){ref-type="fig"} for representative M-modes of the four genotypes). As the mice aged, single heterozygotes progressively exhibited weakened pumping ability, whereas double heterozygotes always performed worse than their single-heterozygous littermates ([Fig. 4, A--D](#fig4){ref-type="fig"}). Collectively, these results demonstrate that cardiac output, as assessed by multiple imaging parameters, is perturbed in *Cdc42* heterozygous mice, and as expected in *Nkx2-5* heterozygotes. Compellingly, these defects are markedly worse when the two alleles are combined in trans, suggesting that Cdc42 and Nkx2-5 synergistically regulate cardiac output and function in the mouse adult heart.

![**Compound haploinsufficiency of mouse *Cdc42 (MmCdc42)* and *Nkx2-5* resulted in defective cardiac contraction and electrophysiological function.** (A--D) Histograms showing echocardiographic parameters of *MmCdc42^+/+^;Nkx2-5^+/+^*, *MmCdc42^+/+^;Nkx2-5^del/+^*, *MmCdc42^del/+^;Nkx2-5^+/+^*, and *MmCdc42^del/+^;Nkx2-5^del/+^* adult mice at 4, 8, and 12 wk. Combined reduction of *Mm*Cdc42 and Nkx2-5 worsened heart function shown as (A) lower fraction shortening (FS), (B) ejection fraction (EF), (C) stroke volume (SV), and (D) cardiac output (CO) at all time points. Unpaired Student's *t* test (relative to wild type): \*, P \< 0.05; \*\*, P \< 0.01. (E) Representative M-mode echocardiograms illustrate decrease in contractility of *MmCdc42^del/+^;Nkx2-5^del/+^* hearts (right panel, larger systole) compared with controls. (F) Table with electrocardiographic parameters of *MmCdc42 and Nkx2-5* combinations in adult mice (± SEM). One-way ANOVA: \*, P \< 0.05; \*\*, P \< 0.01.](JCB_201006114_GS_Fig4){#fig4}

Mouse models of *Nkx2-5* deficiency revealed a critical role for *Nkx2-5* in establishing and maintaining proper cardiac conduction system function ([@bib46]; [@bib13]; [@bib59]), and human mutations in *Nkx2-5* cause conduction-system dysfunction ([@bib55]). Given the interaction between *tinman* and *Cdc42* that we identified in the fly, we hypothesized that *Nkx2-5* also interacts with *Cdc42* in regulating the electrical activity of adult mouse heart. Therefore, we performed surface electrocardiography (ECG) and found that the average heart rate of single and double heterozygotes is not significantly different from that of wild-type mice, nor is there any difference in the delay between atrial and ventricular depolarization as indicated by the PR interval ([Fig. 4 F](#fig4){ref-type="fig"}). However, combined reduction of Cdc42 and Nkx2-5 resulted in prolonged atrial depolarization manifested by increased P duration ([Fig. 4 F](#fig4){ref-type="fig"}). The QRS complex, the portion of an ECG that corresponds to the depolarization of the right and left ventricles, was also significantly prolonged in double heterozygotes and was associated with prolongation of the QT and QTc intervals ([Fig. 4 F](#fig4){ref-type="fig"}). We also noticed that the double heterozygotes showed signs of right bundle branch block based upon S wave depression and the delays, as calculated in [Fig. 4 F](#fig4){ref-type="fig"}, which was not observed in single heterozygotes or wild-type controls. We then examined cardiac structure and fibrosis of these adult mice by performing the standard hematoxylin and eosin (H&E) and Masson Trichrome stainings, but did not observe any consistent differences among different genotypes (unpublished data and [Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201006114/DC1)). Thus, compound heterozygosity for *Nkx2-5* and *Cdc42* does not alter cardiac morphology in the mouse as significantly as in the fly. This could be due to compensatory or redundant mechanisms that may be more prevalent in mammals. Nevertheless, our data show that *Mm Cdc42* interacts strongly with *Nkx2-5* in the mouse heart and that this genetic interaction is essential for proper cardiac contraction, electrical conduction, and rhythmicity.

Screening for *CDC42* gene variants in human cohorts with heart disease
-----------------------------------------------------------------------

The strong evidence in fly and mouse that implicates Cdc42 as an important determinant of normal heart function points to *CDC42* as a candidate gene for human heart disease. Mutations in the human homologue of *tinman*, *NKX2-5*, or other participants in the cardiogenic transcriptional network, *TBX5*, *TBX20*, and *GATA4*, have been associated with a variety of congenital and adult-onset heart disease. In humans, the *CDC42* locus maps to chromosome 1p36. Monosomy 1p36 is the most common terminal deletion syndrome and results in mental retardation and multiple congenital anomalies, including atrial septal defects (ASD), ventricular septal defects (VSD), patent ductus arteriosus (PDA), and dilated cardiomyopathy (DCM). Loss of *CDC42* could possibly account for the cardiac defects of this syndrome, as well as for cases in which these defects occur in isolation. We performed mutation screening of the *CDC42* gene in two heart disease patient populations from Houston (J. Towbin) and Sydney (D. Fatkin).

In the Houston study, 331 subjects with heart disease, including 96 probands with dilated cardiomyopathy (DCM), 48 with hypertrophic cardiomyopathy (HCM), 91 with left ventricular noncompaction (LVNC), and 96 with congenital heart disease (CHD), as well as over 400 controls (over 800 chromosomes), were examined for potential variants in the human *CDC42* gene (GenBank/EMBL/DDBJ accession no. [NM_001791](NM_001791); [Table I](#tbl1){ref-type="table"}). Seven nonsynonymous and seven synonymous variants and four intronic variants were identified. Six out of the seven nonsynonymous variants were polymorphic and identified in subjects and controls. A single rare nonsynonymous variant, c.539A\>G, which is predicted to result in an amino acid change of T125A, was not detected in over 300 Caucasian and over 100 Hispanic controls ([Table I](#tbl1){ref-type="table"}). This variant was found in a sporadic CHD patient with an atrial septal defect (ASD) and a patent ductus arteriosus (PDA). The parents did not participate in the study. In the Sydney study, over 300 heart disease patients (AF, CHD, LVNC) and 100 controls were examined ([Table II](#tbl2){ref-type="table"}), with no apparent disease-causing mutations identified. Some X synonymous variants were identified and no nonsynonymous variants were found.

###### 

Nonsynonymous or synonymous variants identified in *CDC42* (NM_001791) in probands either with DCM, HCM, LVNC, or congenital heart diseases (Houston study)

  Location             Nucleotide change   Amino acid change    Type of variant    Patient group   Frequency                    
  -------------------- ------------------- -------------------- ------------------ --------------- ----------- ------- -------- --------------
  Amplicon1 (Exon 1)   c.188G\>T           V8F                  NP                 6               0           0       0        6/331
                                                                                                                       (1.8%)   
                       c.242A\>C           N26N                 S                  1               0           0       0        1/331
                                                                                                                                (0.3%)
                       c.256G\>A           S30S                 S                  2               0           1       0        3/331
                                                                                                                                (0.9%)
                       c.257G\>C           E31Q                 NP                 46              11          52      29       138/331
                                                                                                                                (41.7%)
                       c.271+6 T\>G        Intron 3 splice ds   NP                 2               5           0       0        7/331
                                                                                                                                (2.1%)
  Amplicon2 (Exon2)    c.272-9 insT        Intron3 splice as    NP                 4               0           0       0        4/331
                                                                                                                       (1.2%)   
                       c.272-7 T\>C        Intron3 splice as    NP                 5               2           0       8        15/331
                                                                                                                                (4.5%)
                       c.272-2 T\>C        Intron3 splice as    NP                 6               0           4       3        13/331
                                                                                                                                (3.9%)
                       c.289 A\>C          A41A                 S                  4               0           2       1        7/331
                                                                                                                                (2.1%)
                       c.295 A\>C          T43T                 S                  5               0           0       0        5/331
                                                                                                                                (1.5%)
                       c.317 T\>C          Y51H                 NP                 1               22          14      10       47/331
                                                                                                                                (14.2%)
  Amplicon4 (Exon 4)   c.502T\>A           L112L                S                  0               0           0       2        2/331
                                                                                                                       (0.6%)   
                       c.513A\>C           Q116P                NP                 5               0           0       1        6/331
                                                                                                                                (1.8%)
                       c.523 C\>T          L119L                S                  7               0           1       2        10/331
                                                                                                                                (3.0%)
                       c.525 G\>A          R120K                NP                 2               0           49      0        51/331
                                                                                                                                (15.4%)
                       c.628 T\>C          Y154Y                S                  5               1           2       0        8/331
                                                                                                                                (2.4%)
                                                                                                                                (rs16826536)
                       **c.539 A\>G**      **T125A**            **Rare variant**   **0**           **0**       **1**   **0**    **1/331**
                                                                                                                                (0.3%)
  Amplicon5 (Exon5)    c.730 T\>G          C188W                NP                 3               0           10      12       25/331
                                                                                                                       (7.5%)   

DCM, dilated cardiac myopathy; HCM, hypertrophic cardiac myopathy; LVNC, left ventricular noncompaction; CHD, congenital heart disease; S, synonymous change; NP, nonsynonymous polymorphism.

###### 

Cdc42 variants identified in 328 individuals with adult and congenital heart disease (Sydney study)

  Location   Variant   Amino acid change   Patient group   Published SNP frequency   Reference                  
  ---------- --------- ------------------- --------------- ------------------------- ----------- -------------- ------------
  Intron 3   −22G\>T   NA                  3 (0.03%)       1 (0.005%)                0           NA             Rs41300114
  Intron 3   −8insT    NA                  3 (0.03%)       8 (0.04%)                 0           NA             Novel
  Intron 3   −3T\>C    NA                  0               0                         1 (0.04%)   3/90 (0.03%)   Rs17837976
  Exon 5     180G\>A   G60G                0               1 (0.005%)                0                          
  Exon 5     276C\>T   N92N                1 (0.01%)       0                         0           1/90 (0.01%)   Rs16826534
  Exon 6     462T\>C   Y154Y               1 (0.01%)       0                         0           4/85 (0.05%)   Rs16826536
  Exon 8     546G\>A   P182P               0               0                         1 (0.04%)   1/85 (0.01%)   Rs16826536

AF, atrial fibrillation; CHD, congenital heart disease; LVNC, left ventricular noncompaction; NA, not available; SNP, single nucleotide polymorphism.

These data indicate that despite the clear biological significance of Cdc42 in the heart, coding sequence variants in the CDC42 gene are not a common cause of CHD or adult heart disease. A possible reason is that this small GTPase is extremely conserved, which does not allow for any sequence variation resulting in an amino acid change to be tolerated, because most may result in lethality. Future mutation screening in intronic and regulatory regions of this gene, resulting in only partial loss of function, and studies in larger patient cohorts will likely provide further insights into the potential role of *CDC42* as a new human heart disease gene.

Cdc42 is a direct target of miR-1 that is negatively regulated by Nkx2-5
------------------------------------------------------------------------

Examination of the upstream regulatory region of mouse miR-1 revealed the presence of four Nkx2-5 consensus binding sites ([Fig. 5 B](#fig5){ref-type="fig"}). This made us wonder whether Cdc42 is regulated by miR-1, which would provide a possible mechanism for the genetic interaction between *Tinman/Nkx2-5* and *Cdc42*. Indeed, we identified a miR-1 consensus target site in the 3′-UTR of *Cdc42* ([Fig. 5 G](#fig5){ref-type="fig"}, see below).

![***MmCdc42* is a direct target of *miR-1* that is negatively regulated by *Nkx2-5*.** (A) Relative levels (RQ) of *miR-1* expression determined by qPCR in HL-1 cells electroporated with *Nkx2-5* compared to control (GFP). (B) A 2.6-kb miR-1-1 enhancer luciferase construct containing four wild-type or mutated Nkx2-5 sites ([@bib67]) was cotransfected with Nkx2-5. (C) qPCR of miR-1 from *Nkx2-5^del/del^* mouse embryos (E9.5) relative to wild-type littermate controls. (D) qPCR of *Cdc42* mRNA levels from HL-1 cells transfected with miR-1 mimic or miR-1 inhibitor. Experiments were done in three biological triplicates and technical quadruplicates. (E) qPCR of *MmCdc42* mRNA from 4 *miR-1* transgenic mouse hearts (αMHC-miR-1) compared with four littermate controls. (F) Western blot of *Mm*Cdc42 protein from αMHC-miR-1 transgenic and control mice. (G) RLA from cells cotransfected with a luciferase reporter---containing wild-type or mutated miR-1 target site in the Cdc42 3′UTR---and a miR-1 mimic or inhibitor. Experiments (each condition) were repeated three times with technical quadruplicates. Unpaired Student's *t* test: \*, P \< 0.05; \*\*, P \< 0.01.](JCB_201006114_GS_Fig5){#fig5}

To determine whether Nkx2-5 is capable of regulating miR-1 transcription we transfected an Nkx2-5 expression construct into HL-1 cells, a line derived from atrial cardiomyocytes ([@bib17]). We found a decrease in *miR-1* levels detected by qPCR ([Fig. 5 A](#fig5){ref-type="fig"}). Similar results were obtained when we transfected Nkx2-5 into primary cardiomyocytes that were directly isolated from neonatal hearts (not depicted). This suggests that Nkx2-5 negatively regulates miR-1 in cardiomyocytes. Furthermore, we identified four conserved Nkx2-5 binding sites in the 2.6-kb minimal enhancer region of miR-1 ([Fig. 5 B](#fig5){ref-type="fig"}). To test whether Nkx2-5 represses miR-1 by binding to these sites, the miR-1 enhancer was cloned upstream of the coding region of a luciferase reporter. A decrease in luciferase activity was observed when the constitutively active reporter was cotransfected with Nkx2-5 into HL-1 cells ([Fig. 5 B](#fig5){ref-type="fig"}). Mutations of the Nkx2.5 binding sites in the miR-1 enhancer abolished Nkx2-5 responsiveness ([Fig. 5 B](#fig5){ref-type="fig"}), suggesting that Nkx2-5 represses miR-1 by directly binding to this enhancer.

Next, we tested whether miR-1 directly regulates *Cdc42* by transfecting HL-1 cells with miR-1 mimics (chemically synthesized double-stranded oligonucleotides that mimic the function of endogenous mature miR-1) and miR-1 inhibitors (modified antisense oligoribonucleotides that inhibit miR-1 function). Overexpression of miR-1 resulted in decreased endogenous *Cdc42* expression, whereas inhibition of miR-1 caused an increased expression of *Cdc42* ([Fig. 5 D](#fig5){ref-type="fig"}), which is consistent with the presence of a conserved miR-1 binding site in the *Cdc42* 3′-UTR ([Fig. 5 G](#fig5){ref-type="fig"}). To test whether miR-1 is capable of directly repressing *Cdc42* via this site, the *Cdc42* 3′-UTR was inserted into the 3′-UTR of a luciferase reporter, downstream of the coding region. Transfection of the *Cdc42* 3′-UTR luciferase reporter with miR-1 mimic into HL-1 cells results in a decrease in luciferase activity, whereas cotransfection with miR-1 inhibitor increases luciferase activity ([Fig. 5 G](#fig5){ref-type="fig"}). A gradient of miR-1 was used to confirm the luciferase activity was dose responsive ([Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201006114/DC1)). Mutations of the miR-1 binding site in the *Cdc42* 3′-UTR abolished miR-1 responsiveness ([Fig. 5 G](#fig5){ref-type="fig"}), suggesting that miR-1 represses *Cdc42* by physically binding to its 3′-UTR.

We extracted RNA and protein from transgenic mice in which miR-1 was overexpressed in the adult heart via the α-MHC promoter (α-MHC*--*miR-1; unpublished mice from the Srivastava laboratory) and examined *Cdc42* mRNA and protein levels. Consistently, miR-1 transgenic hearts showed significantly reduced Cdc42 mRNA and protein levels ([Fig. 5, E and F](#fig5){ref-type="fig"}), suggesting a repressive relationship between miR-1 and Cdc42 in vivo. We did not observe increased Cdc42 expression in miR-1-2 knockout hearts, which might be due to the incomplete depletion of miR-1 expression because of the intact miR-1-1 locus ([@bib68]; unpublished data). Furthermore, we determined miR-1 levels in *Nkx2.5* knockout embryos (E9.5) by qPCR and found an increase in miR-1 levels compared with littermate controls ([Fig. 5 C](#fig5){ref-type="fig"}). These data provide further evidence that the genetic interaction between *Nkx2-5* and *Cdc42* is mediated by miR-1.

We then wondered whether the genetic interaction between *tinman and Cdc42* in *Drosophila* is also governed by a double-inhibitory mechanism involving the fly homologue of *miR-1*. We found that cardiac-specific overexpression of *miR-1* causes an increase in arrhythmias ([Fig. 6, A--D](#fig6){ref-type="fig"}), comparable to cardiac expression of dominant-negative *Cdc42^N17^* ([Fig. 2](#fig2){ref-type="fig"}). In addition, fly hearts with excessive cardiac miR-1 expression exhibit reduced levels of *Cdc42* and *slo* mRNA in the heart ([Fig. 6 E](#fig6){ref-type="fig"}), suggesting that *miR-1*'s influence on heart function includes inhibition of *Cdc42* and one or more potassium channels. In contrast to the mouse, however, we did not identify any miR-1 binding sites in the 3′-UTR of fly *Cdc42*. To test whether fly *Cdc42* regulation by miR-1 is through binding to "seedless" 3'-UTR sequences that lack predicted microRNA recognition elements ([@bib5]), we cloned fly *Cdc42* 3′-UTR into the 3′-UTR of a luciferase reporter and performed luciferase assays in *Drosophila* S2 cells. However, we did not observe consistent and reproducible repression in the presence of *miR-1* (Fig. S4 B). Recent evidence suggests that microRNA target sites may not always be conserved ([@bib29]; unpublished data), even though the pathway overall is likely conserved, as in this case and in a recent report ([@bib33]). Thus, it remains to be determined how microRNAs regulate downstream effectors (such as Cdc42; [Fig. 6 E](#fig6){ref-type="fig"}), directly by cryptic sites or via an unknown possibly indirect mechanism. However, we did find two consensus binding sites for Tinman within the enhancer of fly miR-1, and luciferase assays in S2 cells revealed that these two sites are responsible for the regulation of fly miR-1 by Tinman ([Fig. S5](http://www.jcb.org/cgi/content/full/jcb.201006114/DC1)). Taken together, these data suggest a functionally conserved regulatory pathway involving *tinman--miR-1*--*Cdc42* in establishing cardiac functionality, although some aspects of the molecular mechanisms involved may be different between flies and vertebrates, which could also explain the different severity in phenotypes between flies and mice in our study.

![**Overexpression of miR-1 causes arrhythmias in the adult fly heart.** (A) M-mode traces illustrate arrhythmic heart contractions with cardiac *miR-1* overexpression (*tinCΔ4Gal4/UASmiR-1*). (B--D) Statistical analysis of heart contraction in miR-1--overexpressing adult hearts. (E) Cardiac qPCR of fly *Cdc42* (*DmCdc42*) and potassium channels *slowpoke* (*slo*) with *tinCΔ4Gal4/UASmiR-1*. Heart-specific overexpression of *miR-1* resulted in reduced cardiac expression of *Cdc42* and *slo*. \*, P \< 0.05.](JCB_201006114_GS_Fig6){#fig6}

Discussion
==========

*Drosophila* has been successfully used to study regulatory genetic networks of inductive signals and transcription factors that determine cardiac specification and morphogenesis, but the genetic control of cardiac physiology is only beginning to be investigated. Using a cardiac performance-based genetic screen, we discovered a novel genetic interaction between *Cdc42* and the NK homeobox gene *tinman* in regulating cardiac function in the fly. We have identified a heretofore-unknown requirement for the Rho GTPase *Cdc42* in regulating the establishment of cardiac function in the adult fly. Significantly, this interaction is conserved in mice, where combined reduction of *Cdc42* and *Nkx2-5* caused defects in heart contraction, rhythm, and electrophysiological function. Based on the discovery of the interaction between this Rho GTPase with a cardiogenic transcription factor in maintaining proper cardiac function, it is conceivable that other genetic interactors and potential polygenic contributors to heart disease traits can be identified using the fly as a screening platform.

Cdc42 is a well-characterized GTPase, and has been widely studied in different organs and tissues, ranging from worms to humans. Because *Cdc42* was shown to be involved in regulation of the actin/myosin cytoskeleton in the cells of various organisms, we reasoned that *Cdc42* might also control cardiac cell morphogenesis. In *Drosophila* and mouse we found that complete loss of *Cdc42* in the heart leads to defects in cardiac morphogenesis (unpublished data). In the adult heart, Cdc42 was previously shown to be associated with cardiac myocyte hypertrophy ([@bib18]; [@bib45]; [@bib56]). Recent work shows that Cdc42 plays a protective role against hypertrophy, as conditional deletion of Cdc42 in the adult heart led to greater cardiac hypertrophy and increased incidence of heart failure ([@bib37]). Interestingly, our findings show that interference with *Cdc42* function in the adult fly heart via expression of a dominant-negative form of *Cdc42* is sufficient to induce functional and morphological defects, suggesting that, in addition to interacting with *tinman*, *Cdc42* itself is essential for maintaining normal adult heart structure and function. The specific differences between the fly and the mouse phenotypes in these studies may be attributed to differences in assays as well as to evolutionary changes of *Cdc42* function from insects to vertebrates. However, the fact that *Cdc42* adult-specific mutant fly hearts are defective in Z-line/myofibril assembly is consistent with a previous report in a tissue culture model for cardiac hypertrophy showing that sarcomere units are misassembled in cultured rat cardiomyocytes when *Cdc42* expression is disrupted ([@bib40]; [@bib14]). In addition, *Cdc42* in *Drosophila* interacts with a known downstream effector of *Cdc42*, *Pak*, which participates in actin filament assembly and dynamics ([@bib26]; [@bib4]), thus consistent with a possible role for *Cdc42* in myofibrillar organization.

Similar to our *Cdc42;Nkx2-5* compound heterozygote analysis, it has been shown that mice transheterozygous for loss-of-function alleles of *Nkx2-5* and *Tbx5* also exhibit a synergistic interaction, in particular with respect to the development of the cardiac conduction system ([@bib39]). It is therefore likely that other cardiac transcription factors in combination with new genes will reveal similar patterns of interactions in flies and mammals. Although different model organisms have been used to study cardiac disease, the ability to investigate polygenic traits underlying these diseases in a systematic fashion in the adult is limited. Here, we provide evidence that rigorous screening for modifiers of heart disease can be achieved using *Drosophila*, leading to identification of similar polygenic trait interactions in mammals.

The genetic relationship between fly *Cdc42* with the cardiac determinant *tinman* in regulating adult heart contraction may occur, in part, via modulation of potassium channel gene expression, *dSUR* and *slo*, which have previously been shown to be critical regulators of heart function ([@bib32]; [@bib2]). Indeed, *Cdc42-dSUR or --slo* transheterozygotes show a strong interaction reflected in increased arrhythmias. Interestingly, these transheterozygotes also exhibit disturbances in myofibrillar organization, suggesting these ion channel abnormalities somehow also produce sarcomeric defects, perhaps via a secondary structural remodeling effect. Although there is increasing evidence of such remodeling processes being affected by ion channel defects (unpublished data), the underlying mechanism is not yet understood.

A strong interaction was also observed between the mouse homologues of *Cdc42* and *Nkx2-5* in adult heart function. Most interestingly, double haploinsufficiency of *Cdc42* and *Nkx2-5* led to elongated QRS intervals, which is typical of abnormal conduction along the atrio-ventricular bundle, bundle branches, and Purkinje fibers. The observed elongated QT intervals in compound heterozygotes are also characteristic of long-QT syndrome in humans. These findings suggest a possible contribution of compound haploinsufficiency of Cdc42 and Nkx2-5 in human cardiac conduction diseases.

While attempting to elucidate the mechanistic link between *Cdc42* and *Nkx2-5*, we found that miR-1 directly represses *Cdc42* and that miR-1 itself can be repressed by *Nkx2.5* expression. miR-1 is the first microRNA identified in the heart and plays a conserved role in cardiac morphogenesis, cell cycle, and conduction ([@bib67], [@bib68]). miR-1 null mutant mice showed cardiac conduction defects including widened QRS complex and prolonged QT intervals ([@bib68]), which is also affected in *Cdc42;Nkx2-5* double-heterozygous mice. We speculate that loss or gain of miR-1 function causes an imbalance in gene expression in the heart, including that of *Cdc42*. Decreasing the copy number of the direct miR-1 target *Cdc42*, and that of a direct transcriptional miR-1 repressor, Nkx2-5, apparently destroys a delicate balance in the adult heart, tipping it toward deregulated cardiac function. This does not rule out that other mechanisms are also involved in the genetic interaction between *Cdc42* and *Nkx2-5*. Because *Cdc42* is a direct target of *miR-1* and has a crucial function in modulating hypertrophic responses in the mouse, it will be interesting to test whether miR-1 and other microRNAs play a direct role in adult cardiac hypertrophy. Interestingly, *Cdc42* was also found to be a target of miR-133, which is involved in cardiac hypertrophy ([@bib15]). Thus, the RhoGTPase Cdc42 appears to be directly regulated by two major cardiac microRNAs that are involved in controlling cardiac function and hypertrophy. The synergistic transcriptional activation of the *dSUR* enhancer by Tinman and Cdc42 in vitro ([Fig. 3 G](#fig3){ref-type="fig"}) is consistent with the idea that Cdc42 can act in a coactivating mechanism with Tinman, but this remains to be further investigated.

In conclusion, we have used the power of *Drosophila* genetics to uncover a new, conserved genetic pathway, linking genes with critical heart functions, *tinman/Nkx2-5*, miR-1, and *Cdc42*, to a novel network regulating adult heart physiology and performance. With the fly as a screening platform, it is thus possible to identify new polygenic contributors that ensure normal cardiac function relevant to human heart disease.

Materials and methods
=====================

*Drosophila* stocks
-------------------

The following mutant stocks were used: *Cdc42^3^*/FM6 ([@bib11]); *tin^346^*/TM3-*ftz*-lacZ ([@bib3]); *tin^EC40^*/TM3, Df(3R)*tin*GC14 ([@bib8]); *Pak^6^*/TM3,Sb ([@bib47]); Df(2L)Exel9032/Cyo (indicated as *dSUR/+*), Df(3R)BSC397/TM3,Sb (indicated as *slo/+*), Df(2L)Exel6012 ([@bib51]; Exelixis deficiency deleting both *nmr1* and *nmr2*, also indicated as Df(*nmr*)), and Df(1)Exel6253 (Exelixis deficiency deleting the whole genomic region of *Cdc42*, also indicated as Df(*Cdc42*)). Wild-type control flies are *w^1118^*. Overexpression of transgenes was achieved using the UAS-Gal4 system ([@bib12]). The following Gal4 and UAS lines were used: *twi*-Gal4 (twi\>; [@bib24]), *24B*-Gal4 (24B\>; [@bib12]), the double combination *twi*-Gal4;*24B*-Gal4 (twi24B\>; pan-mesodermal expression; [@bib35]), tinCΔ4-Gal4 ([@bib34]), and UAS-*Cdc42^N17^* ([@bib36]). We used TARGET to temporally and spatially activate gene expression ([@bib38]). In brief, we raised flies (with Gal4, Gal80-ts, and UAS constructs) at 18°C before eclosion; after eclosion we raised adult flies at 29°C for 1 wk and then performed heart function assays.

Mouse stocks
------------

Mice harboring a loss-of-function allele for *Nkx2-5* (*Nkx2-5^del/+^*/*Nkx2.5^tm1Siz^*) have been described previously ([@bib61]). Mice harboring a floxed allele of *Cdc42* (*Cdc42^tm1Yizh^*) have also been described previously ([@bib16]). Cdc42 males were bred to Mef2c-AHF-cre ([@bib62]) females to enable germ line deletion of *Cdc42* (*Cdc42^del/+^*), and offspring that did not inherit the Cre allele were then mated to *Nkx2.5* heterozygous animals to generate compound heterozygous and single heterozygous offspring. For all functional studies detailed below, littermates of each indicated genotype were analyzed.

Immunohistochemistry
--------------------

For fly heart immunohistochemistry, antibody staining was performed as described previously ([@bib25]). In brief, after micro-dissection, fly hearts were fixed in 4% PFA overnight at 4°C. After blocking in 10% BSA (Sigma-Aldrich)/PBS for 1 h, fly hearts were incubated in primary antibodies for 1 h, washed three times (15 min each) with PBT (PBS + 0.5% Triton), and then incubated in secondary antibodies for 1 h. After washing 3 × 15 min in PBT, fly hearts were mounted in VectaShield (Vector Laboratories). Cy3- or FITC-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, Inc.) were used for fluorescent confocal microscopy. All the secondary antibodies were used at 1:200. Fly heart preparations were analyzed using a confocal microscope (model LSM510; Carl Zeiss). Mouse anti--α-Actinin ([@bib54]) was used in this study. For mouse heart immunohistochemistry, after perfusion fix the heart was removed and fixed by immersion in 4% PFA in PBS (diluted from 20% PFA stock; Electron Microscopy Sciences) and routinely processed and paraffin embedded. 5-µm sections were stained with hematoxylin and eosin (H&E) and Masson Trichrome and analyzed for regular morphology and fibrosis. Images were acquired by Zeiss LSM software (for confocal images) or Image-Pro Plus 5.1 (for regular IHC images). Adobe Photoshop was used for image processing; contrast and brightness were adjusted for better visualization.

Electrical pacing in flies
--------------------------

The electrical pacing was conducted as described previously ([@bib64]; [@bib65]). In brief, 50--100 flies were paced with a square wave stimulator at 40 V and 6 Hz for 30 s and scored for heart failure rate, defined as the percentage of flies that either exhibit cardiac arrest or continuous fibrillation immediately after pacing.

Image analysis and M-mode traces on semi-intact fly preparations
----------------------------------------------------------------

Procedures used were as described previously ([@bib42]; [@bib22]). In brief, flies were anesthetized and the head, ventral thorax, and ventral abdominal cuticle were removed. All internal organs except the heart were removed as well as any abdominal fat. Dissections were done under oxygenated saline (108 mM Na^+^, 5 mM K^+^, 2 mM Ca^2+^, 8 mM MgCl~2~, 1 mM NaH~2~PO~4~, 4 mM NaHCO~3~, 10 mM sucrose, 5 mM trehalose, and 5 mM Hepes, pH 7.1). These semi-intact preparations ([@bib43]; [@bib63]) were allowed to equilibrate with oxygenation for 10--20 min before filming. These procedures were performed at room temperature. Image capture of heart contractions was performed using an EM-CCD digital camera (Hamamatsu Photonics) on a microscope (model DM LFSA; Leica) using direct immersion lenses. High-speed movies taken at rates of 100--200 frames per second were acquired and contrast enhanced using Simple PCI imaging software (Compix, Inc.). Movie analysis and M-mode generation was performed using a MatLab-based image analysis program ([@bib42], [@bib43]; [@bib22]; [@bib63]).

Mouse echocardiography
----------------------

The mouse protocol was approved by institutional guidelines (UCSF). All analyses were performed in a blinded fashion for genotype and intervention. Mice were anesthetized with 2.4% isoflurane/97.6% oxygen and placed in a supine position on a heating pad (37°C). Echocardiography was performed by a High-Resolution Micro-Imaging System (Vevo 770; VisualSonics) with a 15-MHz linear array ultrasound transducer. The left ventricle (LV) was assessed in both parasternal long-axis and short-axis views at a frame rate of 120 Hz. End-systole or end-diastole was defined as the phase in which the smallest or largest area of LV, respectively, was obtained. Left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were measured from the LV M-mode tracing with a sweep speed of 50 mm/s at the papillary muscle level.

Mouse electrocardiography
-------------------------

For surface electrocardiography, mice were anesthetized with 1.75% isoflurane at a core temperature of 37--38°C. Four needle electrodes (AD Instruments) were placed subcutaneously in standard limb lead configurations. For each mouse, 10--20 s of continuous signals were sampled at 10 KHz in each lead configuration using a PowerLab4/30 interface (AD Instruments). Data analysis was performed offline using electronic calipers on averaged beats (Chart5Pro v5.4.2; AD Instruments). The QRS interval was measured from the onset of the Q-wave to the isoelectric point preceding the first, rapid repolarization wave. The QT interval was measured from the onset of the Q-wave to the end of the second, slower repolarization wave. The measured QT interval was corrected for heart rate using the rodent correction formula, QTc = QT/(RR/100)0.5.

Quantitative real-time PCR (qPCR)
---------------------------------

For fly qPCR, total RNA was extracted from 20 dissected hearts of 1-wk-old adult females by using TRIzol (Invitrogen). After lysis with TRIzol followed by phase separation, the aqueous phase was subjected to RNA extraction (Mini RNA Isolation kit; Zymo Research) with on-column DNaseI treatment (QIAGEN). After RNA extraction with RNase-free water, the first-strand cDNA was immediately transcribed with SuperScript III (Invitrogen) by using oligo(dT) primer, followed by the second-strand synthesis with DNA polymerase I, *E. coli* DNA ligase, and RNase H. Quantitative PCR was performed using the LightCycler FastStart DNA Master PLUS SYBR Green I kit (Roche). The primer sets were as follows: for *rp49*, 5′-GACGCTTCAAGGGACAGTATCTG-3′ and 5′-AAACGCGGTTCTGCATGAG-3′; for *dSUR*, 5′-CATCACCATTGCCCATCGTCT-3′ and 5′-CGCCCTTCTCCAGTAAACC-3′; for *slowpoke*, 5′-GCCAACAGATCAGGTATTCGT-3′ and 5′-GCGCTACACAGTAACAATCA-3′; for *cdc42*, 5′-CTACACACTGGGCCTGTTC-3′ and 5′-TTTGGCAATGGTGTGTAATC-3′. The following gene expressions did not show any consistent and/or significant difference among the genotypes we tested: potassium channel genes: *shaker*, *shaker-like, seizure*, *Inwardly rectifying potassium channel* (*Ir*), and *KCNQ*; calcium channel and exchanger genes: *cacophony*, *Na/Ca-exchange protein* (*calx*), *Inositol 1,4,5,-tris-phosphate receptor* (*Itp-r83A*), and *Na^+^-driven anion exchanger 1* (*Ndae1*).

For mouse qPCR, RNA was extracted by TRizol method (Invitrogen) from individual hearts. RT-PCR was performed using the Superscript III First-Strand Synthesis System (Invitrogen). qPCR was performed using the ABI 7900HT system (TaqMan; Applied Biosystems), per the manufacturer's protocols. Optimized primers from Taqman Gene Expression Array were used. miRNA RT was conducted using the Taqman MicroRNA Reverse Transcription kit (Applied Biosystems). miRNA real-time PCR (qRT-PCR) was performed per the manufacturer's protocols by using primers from Taqman MicroRNA Assays (Applied Biosystems). Expression levels were normalized to GAPDH expression and miR-16 (microRNA qPCR).

Cell culture, transfection, and luciferase assay
------------------------------------------------

HL-1 cells were maintained in Calycomb Medium supplemented with 100 µM norepinephrine, 10% FBS, and 4 mM [l]{.smallcaps}-glutamine. Cells were maintained at 37°C in a humidified atmosphere of 5% CO~2~/95% air. Lipofectamine 2000 (Invitrogen)--mediated transfection was performed according to Invitrogen's protocol. miR-1 mimic and inhibitor were purchased from Thermo Fisher Scientific. For each transfection in one well of a six-well plate, 40 pmol of mimic or inhibitor was used. For plasmid transfection, 100 ng of plasmid was transfected in one well of a six-well plate using the Amaxa Nucleofection kit (Lonza) per the manufacturer's protocol. Luciferase assays were performed as described previously ([@bib67]) with the Dual-Luciferase Reporter Assay System (Promega). Cdc42 3′-UTR was cloned from mouse genomic DNA with the following primers: 5′-ACTAGTACGC­ATCTCCAGAGC­CCTTTCTGC-3′ and 5′-AAGCTTTAGC­CCTGACTGGTC­CCCATGTTGG-3′. Amplified DNA was cloned into pCRII vector and subsequently cloned into pMIR-REPORT vector (Invitrogen). Site-directed PCR-mediated mutagenesis was performed using the QuickChange II XL Site-Directed Mutagenesis kit (Agilent Technologies). Plasmids containing Tinman and Nkx2.5 have been described previously ([@bib2]; [@bib60]). Tinman cDNA was finally inserted in pUAST vector; Nkx2-5 cDNA was finally inserted in pCDNA3.1 vector. Luciferase constructs containing *miR-1* enhancer and *dSUR* enhancer were described previously ([@bib67]; [@bib2]).

Western blots
-------------

Western blots were performed as described previously ([@bib67]). Rabbit anti-Cdc42 (Cell Signaling Technology) and rabbit anti-GAPDH (Santa Cruz Biotechnology, Inc.) were both used at a 1:1,000 dilution for Western blots. All Western blots were quantified using AlphaImager software from Alpha Innovations.

Statistics
----------

Mean, standard deviation, and standard error of the mean were calculated. Error bars are represented as standard error of the mean. Sample numbers were indicated in corresponding figures. Comparisons between groups were made by one-way ANOVA or unpaired two-tails assuming equal variance *t* test, as applicable. For fly pacing experiments, χ^2^ test was applied.

Human subjects and DNA sequence analysis
----------------------------------------

### Houston study.

The study population from Baylor College of Medicine included 331 unrelated pediatric probands either sporadic or familial cases of heart disease including 96 individuals with dilated cardiomyopathy (DCM), 48 individuals with hypertrophic cardiomyopathy (HCM), 96 individuals with congenital heart disease (CHD), and 91 individuals with either isolated or nonisolated left ventricular noncompaction (LVNC; [Table I](#tbl1){ref-type="table"}). All patients were evaluated by physical examination, chest radiography, electrocardiography, echocardiography, cardiac magnetic resonance imaging (cMRI), and angiography. Left ventricular size and function was evaluated by M-mode and two-dimensional echocardiography, Doppler, and color Doppler analyses. Further details on heart function measures are as described in [@bib53]. All subjects or their guardians provided written informed consent. Blood for EBV-transformed lymphoblastoid cell lines and DNA extraction was obtained, as regulated by the Baylor College of Medicine Institutional Review Board. DNA was extracted either directly from blood or from cultured cells using the Puregene DNA Isolation kit (Genetra Systems) according to the manufacturer's protocol. Primers were designed in to the intron sequences flanking coding exons of *CDC42* (Genbank/EMBL/DDBJ accession no. [NM_001791](NM_001791)). Protein encoding amplicons were amplified by polymerase chain reaction using genomic DNA, as described previously ([@bib53]). PCR products were purified and sequenced by automated sequencing using a DNA sequencer (ABI 3730; Applied Biosystems) and Big Dye terminator chemistry (version 3.1) according to the manufacturer's instructions. The only rare variant we found was T125A in a CHD patient. Over 300 Caucasian and \>100 Hispanic controls were analyzed for all variants identified.

### Sydney study.

The population study in Australia was comprised of 100 individuals with adult-onset familial atrial fibrillation (AF), 200 individuals with CHD, comprised of ventricular septal defect (VSD), *n* = 113; atrial septal defect (ASD), *n* = 59; patent ductus arteriosis (PDA), *n* = 28, and 28 individuals with isolated or syndromic LVNC. Seven sequence variants were identified, including four synonymous amino acid substitutions and three intronic variants. Five of these variants have been reported previously and two were novel ([Table II](#tbl2){ref-type="table"}). Of note, the T125A variant from the Houston study was not detected in any DNA samples from the 328 heart disease patients or in samples from 100 healthy Caucasian volunteers ([Table II](#tbl2){ref-type="table"}). These patient populations were recruited from St. Vincent's Hospital, Darlinghurst, the Kids Heart Research DNA Bank at The Children's Hospital at Westmead, the Royal Prince Alfred Hospital, Camperdown, and the National Australian Childhood Cardiomyopathy Study. 100 healthy Caucasian volunteers comprised a control group. All participants gave informed written consent and study protocols were approved by the relevant institutional Human Research Ethics Committees.

DNA sequencing
--------------

DNA was isolated from patient blood samples using conventional techniques. Protein-coding sequences and adjacent intronic sequences of the CDC42 gene were amplified by polymerase chain reaction from genomic DNA using primers derived from intron sequences. Amplimers were purified and sequenced using the Big Dye terminator and were analyzed on a DNA Analyzer (ABI PRISM 3700; Applied Biosystems) at the Ramaciotti Centre for Gene Function Analysis (University of New South Wales, Kensington, New South Wales, Australia).

Online supplemental material
----------------------------

Fig. S1 describes how *Cdc42* interacts with *Pak* to regulate actin filament alignment and cardiac function in fly adult heart and *Cdc42* does not interact with *nmr/Tbx20* in maintaining proper heart function. Fig. S2 shows regulation of ion channel genes *dSUR* and *slowpoke* by *Cdc42* and *tinman*. Fig. S3 shows cardiac morphology and fibrosis of *MmCdc42^+/+^;Nkx2-5^+/+^*, *MmCdc42^+/+^;Nkx2-5^del/+^, MmCdc42^del/+^;Nkx2-5^+/+^*, and *MmCdc42^del/+^;Nkx2-5^del/+^* adult mice. Fig. S4 shows additional luciferase assays to test regulation of *Cdc42* by miR-1. Fig. S5 shows regulation of fly miR-1 by Tinman. Table S1 shows the cardiac arrest or fibrillation rate for deficiency lines covering chromosome X and part of chromosome II. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201006114/DC1>.
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